Pharma Business - March 20, 2023
Orion’s darolutamide approved for additional prostate cancer indication in China
The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing […]
Pharma Business - March 15, 2023
Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials
Novo Nordisk has announced it is lowering the US list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes. Products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir, Novolin, NovoLog and NovoLog Mix 70/30. Novo Nordisk is […]
Agreement - March 7, 2023
Affibody and Chiesi Group collaborate
Affibody and Chiesi Group have announced the execution of a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s technology. Under the terms of the agreement, the parties will collaborate closely to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will […]
Pharma Business - March 7, 2023
Novo Nordisk to expand R&D presence
Novo Nordisk has announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of its largest R&D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based […]
Intellectual Property - March 2, 2023
Diamyd Medical receives patent protection in the US and Japan
The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the company’s oral formulation of the GABA-based study drug Remygen. Remygen is currently in Phase 2 development through the ReGenerate-1 trial in individuals with long-term Type 1 Diabetes. Results are expected later […]
Drug Development Pharma - March 1, 2023
EHDEN and Lundbeck start first research programme
The European Health Data and Evidence Network (EHDEN) and Lundbeck have begun formative stages of neuroscience research with the EHDEN network and potential partners, including other pharma companies. Lundbeck joined the IMI EHDEN Consortium on 1st September 2022 and is now the first partner to join the neuroscience research programme. “This partnership will contribute to the neuroscience ecosystem […]
